Chemistry:Milsaperidone

From HandWiki

Milsaperidone (INN, USAN), also known by its developmental code name VHX-896 and the brand name Bysanti, is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar disorder.[1] It is also in phase 3 clinical trials for treatment of major depressive disorder.[2][3][4] It is a prodrug of iloperidone (Fanapt) and acts as a dopamine D2 receptor and serotonin 5-HT2A receptor antagonist, among other actions.[2][5][6] The drug was developed by Vanda Pharmaceuticals.[2]

See also

References

  1. ↑ "FDA Approves Milsaperidone for Treatment of Bipolar I Disorder and Schizophrenia". 3 March 2026. https://www.pharmacytimes.com/view/fda-approves-milsaperidone-for-treatment-of-bipolar-i-disorder-and-schizophrenia. 
  2. ↑ 2.0 2.1 2.2 "Vanda Pharmaceuticals". 30 July 2025. https://adisinsight.springer.com/drugs/800064652. 
  3. ↑ "Depressive disorders: systematic review of approved psychiatric medications (2009-April 2025) and pipeline phase 3 medications". BMC Psychiatry 25 (1). October 2025. doi:10.1186/s12888-025-07141-3. PMID 41057811. 
  4. ↑ "Med Check: FDA Accepts Bysanti Application, Cobenfy Fails as Adjunct, and More". Psychiatric News 60 (6). 1 June 2025. doi:10.1176/appi.pn.2025.06.6.2. ISSN 0033-2704. https://psychiatryonline.org/doi/10.1176/appi.pn.2025.06.6.2. Retrieved 11 October 2025. 
  5. ↑ "Milsaperidone Under Review for Bipolar I Disorder and Schizophrenia". 9 May 2025. https://www.empr.com/news/milsaperidone-under-review-for-bipolar-i-disorder-and-schizophrenia/. 
  6. ↑ "Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026". 5 May 2025. https://www.biospace.com/press-releases/vanda-announces-bysanti-nda-filing-fda-decision-expected-in-early-2026. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Milsaperidone&oldid=4358972"